11:14 AM EST - Arch Biopartners Inc. : Announced that it will seek regulatory guidance from the U.S. Food and Drug Administration in a pre-Investigational New Drug application meeting (pre-IND meeting) for AB569, the company’s drug candidate for treating antibiotic resistant bacterial infections in the lungs, wounds and urinary tract. Arch Biopartners Inc.
shares V.ARCH are trading up $0.13 at $1.48.
